GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today the publication of pre-clinical research demonstrating the selective delivery of TNF-alpha to tumors. Combining a new, targeted adenovector with selective regulation of gene expression achieved a high degree of anti-tumor activity and selectivity in animal models of disseminated ovarian cancer.
